Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409582 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL16011494 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31544535 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31437121 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL14957270 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL13403896 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL17843660 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL34141 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL2531873 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL30074388 | 1.00 | KMT2A (0.70) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011102-A | Cyclic peptide ligand of target asialoglycoprotein receptor, pharmaceutically acceptable salt thereof and application and pharmaceutical composition thereof | 浙江大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12599684-B2 | Molecular probes and methods of use | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250346559-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | SIGNDO BIOTECHNOLOGY (SUZHOU) CO., LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4644369-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | SIGNDO BIOTECHNOLOGY (SUZHOU) CO., LTD (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-120058842-A | Radionuclide coupling cyclic peptide of targeted tumor uPAR, and preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-30 | — | — | CN | disclosed |
| CN-120000817-A | Nuclide drug targeting tumor stem cell CD133, and labeling precursor, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-16 | — | — | CN | disclosed |
| CN-120004985-A | Tumor uPA targeting nuclide coupled cyclopeptide ligand, and preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025083069-A1 | HER2-BINDING MOLECULES | Hummingbird Bioscience Pte. Ltd. (SG) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025083071-A2 | ANTIBODY-DRUG CONJUGATES | Hummingbird Bioscience Pte. Ltd. (SG) | 2025-04-24 | — | — | WO | disclosed |
| CN-118978470-B | Compound and preparation method, composition, kit and application thereof | 新斗生物科技(苏州)有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-2010052144-A2 | NEUROPEPTIDE-2-RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| EP-2119455-A1 | Tripartite raftophilic structures and their use | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-1732612-B1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADO TECHNOLOGIES GMBH (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113386-A1 | PEPTIDE CONJUGATES | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| US-20070231258-A1 | Peptide conjugates | KARYON CTT LTD. (FI) | 2007-10-04 | — | — | US | disclosed |
| EP-1732612-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | Jadolabs Gmbh (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097199-A1 | TRIPARTITE CONJUGATES CONTAINING A STRUCTURE INTERACTING WITH CELL MEMBRANE RAFTS AND THEIR USE | JADOLABS GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317767-A1 | Tripartitle Raftophilic Strutures and their Use | FGB, CLTB, CD38 | KMT2A 2719/4885SMN1; SMN2 2442/4885LMNA 2380/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | KMT2A 3586/4885SMN1; SMN2 3998/4885LMNA 3163/4885 |
| US-20250346559-A1 | COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION, KIT AND USE THEREOF | KIT, CD81, SLC7A1 | KMT2A 1489/4885SMN1; SMN2 2703/4885LMNA 2636/4885 |
| US-20070231258-A1 | Peptide conjugates | PTMS, QPCT, CTH | KMT2A 3390/4885SMN1; SMN2 2623/4885LMNA 4879/4885 |
| US-12599684-B2 | Molecular probes and methods of use | TFRC, FGB, SSTR3 | KMT2A 3714/4885SMN1; SMN2 3215/4885LMNA 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.